Alpha Teknova (NASDAQ:TKNO), a specialist in custom bioprocess solutions for the life sciences sector, released its results on August 7, 2025. The most important news: Revenue (GAAP) rose by 7%, reaching $10.3 million, and net loss per share (GAAP) narrowed to $0.07, both of which (GAAP) surpassed market expectations. Analysts had forecast a $0.10 loss per share (GAAP) and $10.3 million in GAAP revenue. The quarter featured positive developments in margin expansion and operational efficiency, signaling ongoing improvement, although the company continued to report net losses.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

Alpha Teknova (NASDAQ:TKNO) provides highly customized reagents and solutions for researchers and developers in the biotechnology, pharma, and diagnostics fields. The company manufactures products such as custom research-use-only media, buffers, and components used in key segments of life sciences including cell and gene therapies, mRNA vaccines, and molecular diagnostics.

Continue reading

Source Fool.com